Lila Madjour
About Lila Madjour
Lila Madjour is a Regulatory Affairs Pharmacist currently working at Septodont in France and Bristol-Myers Squibb in New Jersey, United States. She has over a decade of experience in drug safety and pharmacovigilance, holding various roles in major pharmaceutical companies in both the United States and France.
Title and Current Positions
Lila Madjour is a Regulatory Affairs Pharmacist who currently holds two positions. She works at Septodont as a Regulatory Projects Executive in France and at Bristol-Myers Squibb as a Regulatory Affairs Pharmacist in New Jersey, United States.
Professional Background
Lila Madjour has extensive experience in regulatory affairs and drug safety. She has worked in various roles across several major pharmaceutical companies in both the United States and France. Her career began with Sanofi as a Clinical Area Safety Pharmacist, where she worked for four months in 2009. Lila then worked briefly at Call Medi-call as a Medical Information Phoning professional for two months in 2009. She moved on to Pfizer, serving as a Pharmacovigilance Expert for seven months in 2010 in New York, New York. Lila later held positions at LFB and Merck in drug safety roles before joining Septodont in January 2015.
Education and Expertise
Lila Madjour has a solid educational foundation in toxicology and healthcare, having earned a Master's degree from Paris-Sud University (Paris XI). From 2008 to 2010, she studied various aspects of toxicology and healthcare, providing her with the expertise required for her roles in regulatory affairs, drug safety, and pharmacovigilance.
Experience in Drug Safety and Pharmacovigilance
Throughout her career, Lila Madjour has held multiple roles focused on drug safety and pharmacovigilance. Her early experience includes a position at Sanofi as a Clinical Area Safety Pharmacist in 2009. She also worked at Pfizer as a Pharmacovigilance Expert in 2010 and held drug safety roles at LFB and Merck in subsequent years. These roles have involved ensuring the safe usage of pharmaceutical products, monitoring adverse drug reactions, and adhering to regulatory requirements.